AR121457A1 - VARIANTES DE a-GALACTOSIDASA HUMANA - Google Patents
VARIANTES DE a-GALACTOSIDASA HUMANAInfo
- Publication number
- AR121457A1 AR121457A1 ARP210100519A ARP210100519A AR121457A1 AR 121457 A1 AR121457 A1 AR 121457A1 AR P210100519 A ARP210100519 A AR P210100519A AR P210100519 A ARP210100519 A AR P210100519A AR 121457 A1 AR121457 A1 AR 121457A1
- Authority
- AR
- Argentina
- Prior art keywords
- human
- galactosidase activity
- engineered polypeptides
- possessing human
- polypeptides possessing
- Prior art date
Links
- 102000005840 alpha-Galactosidase Human genes 0.000 abstract 3
- 108010030291 alpha-Galactosidase Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención presenta polipéptidos manipulados que poseen actividad a-galactosidasa humana y sus composiciones. Se han optimizado los polipéptidos manipulado que poseen actividad a-galactosidasa humana a fin de mejorar la termoestabilidad, la estabilidad sérica, la captura celular, la estabilidad bajo ambas condiciones ácidas (pH < 4) y básicas (pH > 7), inmunogenicidad reducida, y mejorada eliminación de globotriaosilceramida de las células. Asimismo, la invención se refiere al uso de las composiciones que comprenden polipéptidos manipulados que poseen actividad a-galactosidasa humana con propósitos terapéuticos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982949P | 2020-02-28 | 2020-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121457A1 true AR121457A1 (es) | 2022-06-08 |
Family
ID=77463498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100519A AR121457A1 (es) | 2020-02-28 | 2021-02-26 | VARIANTES DE a-GALACTOSIDASA HUMANA |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210269787A1 (es) |
| EP (1) | EP4110926A2 (es) |
| JP (1) | JP2023516301A (es) |
| KR (1) | KR20220146601A (es) |
| CN (1) | CN116096898A (es) |
| AR (1) | AR121457A1 (es) |
| AU (1) | AU2021228689A1 (es) |
| BR (1) | BR112022016990A2 (es) |
| CA (1) | CA3173294A1 (es) |
| CL (1) | CL2022002330A1 (es) |
| CO (1) | CO2022012809A2 (es) |
| EC (1) | ECSP22075305A (es) |
| IL (1) | IL295818A (es) |
| MX (1) | MX2022010663A (es) |
| PE (1) | PE20230487A1 (es) |
| TW (1) | TW202146648A (es) |
| WO (1) | WO2021173928A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3898960A4 (en) | 2018-12-20 | 2022-11-30 | Codexis, Inc. | VARIANTS OF HUMAN ALPHA GALACTOSIDASE |
| WO2024042485A1 (en) * | 2022-08-25 | 2024-02-29 | Takeda Pharmaceutical Company Limited | Composition for use in the treatment of fabry disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2361631A1 (en) * | 2002-04-25 | 2011-08-31 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
| US9194011B2 (en) * | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| EP4234699A1 (en) * | 2014-12-22 | 2023-08-30 | Codexis, Inc. | Human alpha-galactosidase variants |
| AU2020327019A1 (en) * | 2019-08-07 | 2022-03-03 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
-
2021
- 2021-02-26 AU AU2021228689A patent/AU2021228689A1/en active Pending
- 2021-02-26 CN CN202180017455.2A patent/CN116096898A/zh active Pending
- 2021-02-26 MX MX2022010663A patent/MX2022010663A/es unknown
- 2021-02-26 KR KR1020227033613A patent/KR20220146601A/ko unknown
- 2021-02-26 TW TW110107124A patent/TW202146648A/zh unknown
- 2021-02-26 BR BR112022016990A patent/BR112022016990A2/pt unknown
- 2021-02-26 EP EP21761023.7A patent/EP4110926A2/en active Pending
- 2021-02-26 CA CA3173294A patent/CA3173294A1/en active Pending
- 2021-02-26 WO PCT/US2021/019811 patent/WO2021173928A2/en active Application Filing
- 2021-02-26 US US17/186,462 patent/US20210269787A1/en active Pending
- 2021-02-26 JP JP2022551638A patent/JP2023516301A/ja active Pending
- 2021-02-26 IL IL295818A patent/IL295818A/en unknown
- 2021-02-26 AR ARP210100519A patent/AR121457A1/es unknown
- 2021-02-26 PE PE2022001808A patent/PE20230487A1/es unknown
-
2022
- 2022-08-25 CL CL2022002330A patent/CL2022002330A1/es unknown
- 2022-09-08 CO CONC2022/0012809A patent/CO2022012809A2/es unknown
- 2022-09-27 EC ECSENADI202275305A patent/ECSP22075305A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202146648A (zh) | 2021-12-16 |
| JP2023516301A (ja) | 2023-04-19 |
| BR112022016990A2 (pt) | 2022-10-25 |
| KR20220146601A (ko) | 2022-11-01 |
| PE20230487A1 (es) | 2023-03-21 |
| EP4110926A2 (en) | 2023-01-04 |
| CA3173294A1 (en) | 2021-09-02 |
| CO2022012809A2 (es) | 2022-09-20 |
| IL295818A (en) | 2022-10-01 |
| WO2021173928A3 (en) | 2021-09-30 |
| CN116096898A (zh) | 2023-05-09 |
| AU2021228689A1 (en) | 2022-09-01 |
| US20210269787A1 (en) | 2021-09-02 |
| ECSP22075305A (es) | 2022-12-30 |
| CL2022002330A1 (es) | 2023-03-03 |
| MX2022010663A (es) | 2022-09-23 |
| WO2021173928A2 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121457A1 (es) | VARIANTES DE a-GALACTOSIDASA HUMANA | |
| CO2021009297A2 (es) | Variantes de alfa-galactosidasa humana | |
| AR114445A1 (es) | Conjugados de il-15, y sus usos | |
| ME00183B (me) | Novi postupak za deregulaciju amiloida | |
| BRPI0613770A2 (pt) | anticorpos anti-cd26 e métodos de uso destes | |
| ECSP088591A (es) | Anticuerpos anti-il-23 humanos, composiciones, metodos y usos | |
| BRPI0611793A2 (pt) | anÁlogos de epÍtopo | |
| MEP53308A (en) | Novel peptides that bind to the erythropoietin receptor | |
| BR112013003522A8 (pt) | "polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, uso, método de preparação, bem como ácido nucleico codificando os mesmos" | |
| BRPI0806185A2 (pt) | anticorpo neutralizador de alta potência, fragmento de um anticorpo, molécula de ácido nucléico, vetor, célula, clone de célula b imortalizado, epìtopo, polipeptìdio imunogênico, método para produção de anticorpos, composição farmacêutica, uso de um primeiro anticorpo ou fragmento, composição ou uso, método para tratamento de um sujeito, kit para diagnóstico de infecção por hcmv, método para preparação de uma célula recombinante, método para produção de anticorpos, método de detecção de polipeptìdios e epìtopo que se liga especificamente a um anticorpo | |
| ATE544848T1 (de) | Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais) | |
| EA201792602A1 (ru) | Стволовые клетки плацентарного происхождения и их применение для восстановления регенеративного механизма, коррекции протеомных дефектов и продления жизни стареющих индивидуумов | |
| EA201590611A1 (ru) | Новые молекулы, связывающие il-17a, и их медицинское применение | |
| DK95482A (da) | Fremgangsmaade til fremstilling af aroylimidazoloner | |
| UY27852A1 (es) | Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
| WO2011063320A3 (en) | Recombinant filaggrin polypeptides for cell importation | |
| ATE389397T1 (de) | Adjuvante zusammensetzungen | |
| BR112016011930A2 (pt) | combinações de peptídeos e seus usos em tratamento de alergia de ácaro de poeira | |
| ES2172668T3 (es) | Utilizacion de nuevas composiciones de vidrio para la preparacion de pilares dentales en vidrio y de pilares de soporte y procedimiento para la fabricacion de los pilares de vidrio. | |
| BR112016014069A2 (pt) | receptor de células t (tcr); ácido nucleico; célula não ocorrendo naturalmente e/ou purificada e/ou manipulada; composição farmacêutica; e tcr ou célula | |
| DE602005020147D1 (de) | Detektion von verkürzungsmutationen durch massenspektrometrie | |
| Sánchez et al. | Molecular techniques integrated to the entomological surveillance of Chagas disease vectors: study of the secondary vector Triatoma sordida in the Eastern Region of Paraguay | |
| Ibanez et al. | Presence of the genus Napaeus (Gastropoda: Pulmonata: Enidae) living in all the islands of the Canarian archipelago: Napaeus lichenicola sp. nov. from Fuerteventura island | |
| Dea-Ayuela et al. | Immunoproteomic analysis of Trichinella spiralis larval crude antigens recognized by sera from patients with trichinellosis after treatment with albendazole. | |
| Fernández | Past and future: Reframing Catalan studies in the Mediterranean |